secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2025-07-23T23:59:59+00:00
Accession:  0000950170-25-097885
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics Q2 net loss $65.6M; Phase 3 VANQUISH obesity trial underway
-------------------------------------------------------------------------------

- Net loss $65.6M ($0.58/share) vs $22.3M ($0.20) in Q2 2024; R&D spend $60.2M vs $23.8M.
- Cash and investments $808M as of June 30, 2025, down from $903M at Dec 31, 2024.
- Phase 3 VANQUISH program initiated: two placebo-controlled trials (obesity and obesity+type 2 diabetes) targeting ~5,600 patients.
- Phase 2 VENTURE-Oral dosing trial enrollment completed (~280 patients); top-line results expected 2H25.
- Amylin agonist program progressing; IND filing planned for Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017025097885/0000950170-25-097885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017025097885/vktx-20250723.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-097885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer